Asst/Prof Anna Kemp
Research Assistant Professor
School of Population Health
- Contact details
- School of Population Health
The University of Western Australia (M431)
35 Stirling Highway
CRAWLEY WA 6009
- 6488 8667
- 6488 1188
- BA PhD Murd.
- Assistant Professor Anna Kemp joined the Centre for Health Services at The University of Western Australia in 2007. Her primary research interest is the utilisation of publically subsidised prescription medicines in Australia and the impact of national health policy on their use, particularly among vulnerable population groups. Her other research activities are the analysis of whole-population prescription data, cost barriers to medicines use, methods for analysing policy impacts, pharmaco-vigilance and medicines safety, and health outcomes studies using linked health data. She has a growing reputation within Australian pharmacoepidemiology and pharmaceutical policy research and she is committed to contributing to community health and wellbeing through her research.
- Key research
- Impact of Pharmaceutical Benefits Scheme (PBS) policy changes on utilisation of prescription medicines and health services, utilisation of endocrine therapies for breast cancer, utilisation of opioids, analysis of linked health datasets
- Pratt, N, Ramsay E, Kemp A, Ellett LK, Shakib S, Caughey G, Huang N, Ryan P, Graves S, Roughead EE. Ranibizumab associated with increased risk of stroke but not myocardial infarct: a case series analysis. Drug Safety (accepted 24/7/2014).
Whyatt D, Tenneti R, Marsh J, Kemp A, Firth L, Murray K, Turlach B, Vickery A. The ecological fallacy of the role of age in chronic disease and hospital demand. Medical Care (accepted 5/7/2014).
Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Malacova E, Roughead EE. Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? SpringerPlus 2014; 3:282 doi:10.1186/2193-1801-3-282.
Malacova, E. Kemp A, Jama Alol K, Hart, R. Preen, D. Long-term risk of ectopic pregnancy varies by method of tubal sterilization: a whole-population study. Fertility and Sterility 2014; 101(3), 728-734.
Kemp A, Preen DB, Saunders C, Boyle F, Bulsara M, Holman CDJ, Malacova E, Roughead EE. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. PLoS ONE 2014; 9(1): e84835.
Rogers KD, Kemp A, McLachlan AJ, Blythe F. Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS ONE 2014; 8 (12), e80095.
Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D, Tran D. Pharmacotherapy for smoking cessation, Maternal Use of Medications and Safety: protocol for the Smoking MUMS Study. BMJ Open 2013;3:e003692. doi:10.1136/bmjopen-2013-003692.
Kemp A, Preen DB, Morlet N, Clark A, McAllister IL, Briffa T, Sanfilippo F, Ng JQ, McKnight C, Reynolds W, Gillies MC. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina, 2013, 33 (5) 920-927.
Kemp A, Glover J, Preen DB, Bulsara M, Semmens J, Roughead EE. From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia. Australian Health Review, 2013; 37, 4-10.
Kemp A, Preen DB, Saunders C, Holman CDJ, Bulsara M, Rogers KD, Roughead EE. Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia. BMC Medical Research Methodology, 2013; 13,17.
Kemp A, Preen DB, Glover J, Semmens J, Roughead EE. Impact of cost of medicines for chronic conditions on low income households in Australia. Journal of Health Services Research and Policy 2013; 18 (1): 21–27.
Boudville N, Kemp A, Moody H, Fasset RG, Pedagos E, Nelson C, Healy H, Mangos G, Kirkland G, Kay T, Champion de Crespigny P, Hoffman D, Waugh D. Factors associated with chronic kidney disease progression in Australian Nephrology practices. Nephron, Nephron Clin Pract, 2012;121:c36–c41.
Kemp A, Preen D, Rogers K, Saunders C, Holman CDJ, Bulsara M, Roughead E. Identifying cases of early breast cancer in Australia using prescription and other health service claims and self-report. Pharmacoepidemiology and Drug Safety 2012; 21 (Supplement 3), 8.
Kemp A, Glover J, Preen D, Bulsara M, Semmens J, Roughead E. Have increases in co-payments for medicines further burdened Australians in remote and disadvantaged areas? Pharmacoepidemiology and Drug Safety 2012; 21 (Supplement 3), 294-295.
Einarsdóttir K, Kemp A, Haggar FA, Moorin RE, Gunnell AS, Preen DB, Stanley FJ, Holman CDJ. Increase in caesarean deliveries after the Australian private health insurance incentive policy reforms. PLoS ONE 2012; 7 (7), e41436.
Boudville N, Kemp A, Clayton P, Lim W, Badve SV, Hawley CM, McDonald SP, Wiggins KJ, Bannister KM, Brown FG, Johnson DW. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. Journal of the American Society of Nephrology, 2012; 23, 1398-1405.
Einarsdottir K, Kemp A, Haggar F, Preen DB, Moorin R, Holman D. The impact of federal health care policy on Western Australian birth rates. Australasian Epidemiologist 2011; 18 (3), 55.
Kemp A, Preen DB, Glover J, Semmens J, Roughead E. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Australian Health Review; 2011; 35, 341-349.
Kemp A, Preen DB, Sanfilippo FM, Glover J, Semmens J, Roughead EE. Evaluating pharmaceutical policy impacts using interrupted time series analysis: an Australian case study. International Public Health Journal 2011; 3 (2), 229-241.
Kemp A, Preen DB, Glover J, Semmens J, Roughead E. The impact of pharmaceutical policy changes on utilisation of medicines in Australia: An analysis of administrative health data. International Journal of Longitudinal and Life Course Studies 2010; 1 (3), 61.
Preen DB, Moorin RE, Einarsdottir K, Kemp A, Gibson D. Approaches to health services research and health policy evaluation using longitudinal, whole-population medical record linkage. International Journal of Longitudinal and Life Course Studies 2010; 1(3), 59.
Kemp A, Roughead EE, Preen DB, Glover J, Semmens J. Low income workers face the largest cost burden for prescription medicines in Australia.
Pharmacoepidemiology and Drug Safety 2010; 19 (1), 219.
Pont LG, Kemp A, Roughead EE. Does a National Medicines Policy improve medicines access and utilisation? Pharmacoepidemiology and Drug Safety 2010; 19 (1), 291-292.
Kemp A, Roughead E, Preen DB, Glover J, Semmens J. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. Journal of Health Services Research and Policy 2010; 15 (2), 106-114.
*Hynd A, Roughead E, Preen DB, Glover J, Bulsara M, Semmens J. The impact of increased PBS co-payments on medication dispensings in Western Australia. Australian and New Zealand Journal of Public Health; 2009; 33 (3), 246-252.
Hynd A, Roughead E, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment changes on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiology and Drug Safety 2008; 17 (11), 1091-1099.
*Anna Kemp, formerly Hynd.
- Roles, responsibilities and expertise
- Member, Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee
Research Advisor, Population Health Research Network (PHRN) Proof of Concept (PoC) Reference Group
School of Population Health Consumer and Community Advisory Council
- Funding received
- Roughead E, Ryan P, Graves S, Pratt N, Shakib S, Caughey G, Huang N, Kemp A. Centre of excellence in post-marketing surveillance of medicines and devices. NHMRC Centre for Research Excellence 2013-2017: $2.5 million.
Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D. Pharmacotherapy for smoking cessation during pregnancy and the inter-pregnancy period: a population-based cohort study. NHMRC Project Grant 2012-2016: $620,950.
Preen D, Roughead L, Saunders C, Kemp A, Bulsara M, Holman CDJ. Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian clinical practice. Cancer Australia 2011-2013: $466,498 (2011 $193,070; 2012 $136,714; 2013 $136,714).
Preen DB, Kemp A, Briffa T, Sanfilippo FM, Morlet N. Does treatment of age-related macular degeneration with intravitreal injection of vascular endothelial growth factor inhibitors increase arterial thromboembolic events? NSW Save Sight Institute, 2011: $53,764.
Kemp A, Ng J, 2009, '2010 - Does Treatment of Age-Related Macular Degeneration with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors Increase Arterial Thromboembolic Events?', UWA Research Development Award Scheme, Funds Approved: $29,579.00.
- International Society of Pharmacoepidemiology
Australasian Epidemiological Association
Medicines Use Research Australia
- Previous positions
- Deputy Chair, Faculty of Medicine, Dentistry and Health Sciences Regional Human Research Ethics Committee.
Visiting Research Fellow, The Sax Institute, Sydney.
Visiting Research Fellow, Illawarra Health and Medical Research Institute, University of Wollongong.
- Useful links
- New and noteworthy
- Invited commentary:
Kemp A. Would automating the PBS safety net help to address consumers’ out of pocket costs? Health Voices, 2013; 12, 29-30, https://www.chf.org.au/pdfs/chf/HealthVoices_APRIL_WEB.pdf
Kemp A. Why automating the PBS safety net will be good for everyone. The Conversation, 4 October 2012, https://theconversation.edu.au/why-automating-the-pbs-safety-net-will-be-good-for-everyone-3381
Kemp A, Preen DB, Sanfilippo FM, Glover J, Semmens J, Roughead EE. Evaluating pharmaceutical policy impacts using interrupted time series analysis. In Bell E, Westert G, Merrick J (eds.) Translational Research for Primary Healthcare. 2012. New York: Nova Science, pp. 73-87.
- Current projects
- Endocrine therapy for early breast cancer: utilisation and outcomes in Australian practice.
- Research profile
Research profile and publications